210 related articles for article (PubMed ID: 28674438)
1. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations.
Kulemann B; Rösch S; Seifert S; Timme S; Bronsert P; Seifert G; Martini V; Kuvendjiska J; Glatz T; Hussung S; Fritsch R; Becker H; Pitman MB; Hoeppner J
Sci Rep; 2017 Jul; 7(1):4510. PubMed ID: 28674438
[TBL] [Abstract][Full Text] [Related]
2. [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor].
Timme-Bronsert S; Bronsert P; Werner M; Kulemann B; Höppner J
Pathologe; 2018 Dec; 39(Suppl 2):311-314. PubMed ID: 30483865
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
6. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
7. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells found in patients with localized and advanced pancreatic cancer.
Kulemann B; Pitman MB; Liss AS; Valsangkar N; Fernández-Del Castillo C; Lillemoe KD; Hoeppner J; Mino-Kenudson M; Warshaw AL; Thayer SP
Pancreas; 2015 May; 44(4):547-50. PubMed ID: 25822154
[TBL] [Abstract][Full Text] [Related]
9. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker.
Song BG; Kwon W; Kim H; Lee EM; Han YM; Kim H; Byun Y; Lee KB; Lee KH; Lee KT; Lee JK; Jang JY; Park JK
Front Oncol; 2020; 10():616440. PubMed ID: 33680936
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
13. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
14. Not all mutations of
Li W; Liu Y; Cai S; Yang C; Lin Z; Zhou L; Liu L; Cheng X; Zeng W
Int J Clin Exp Pathol; 2019; 12(3):957-967. PubMed ID: 31933906
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma.
Liu H; Sun B; Wang S; Liu C; Lu Y; Li D; Liu X
Cell Physiol Biochem; 2017; 42(1):373-382. PubMed ID: 28558380
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
